Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates Metabolic Dysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1
Open Access
- 7 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5086
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common metabolic disease of the liver, characterized by hepatic steatosis in more than 5% of hepatocytes. However, despite the recent approval of the first drug, resmetirom, for the management of metabolic dysfunction-associated steatohepatitis, decades of target exploration and hundreds of clinical trials have failed, highlighting the urgent need to find new druggable targets for the discovery of innovative drug candidates against MASLD. Here, we found that glutathione S-transferase alpha 1 (GSTA1) expression was negatively associated with lipid droplet accumulation in vitro and in vivo. Overexpression of GSTA1 significantly attenuated oleic acid-induced steatosis in hepatocytes or high-fat diet-induced steatosis in the mouse liver. The hepatoprotective and anti-inflammatory drug bicyclol also attenuated steatosis by upregulating GSTA1 expression. A detailed mechanism showed that GSTA1 directly interacts with fatty acid binding protein 1 (FABP1) and facilitates the degradation of FABP1, thereby inhibiting intracellular triglyceride synthesis by impeding the uptake and transportation of free fatty acids. Conclusion: GSTA1 may be a good target for the discovery of innovative drug candidates as GSTA1 stabilizers or enhancers against MASLD.Keywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (2022-I2M-2-002, 2021-I2M-1-028, 2018ZX09711001-003-010, 82304585)
- National Mega-Project for “R&D for Innovative drugs”, Ministry of Science and Technology, China (2022-I2M-2-002, 2021-I2M-1-028, 2018ZX09711001-003-010, 82304585)
- National Natural Science Foundation, China (2022-I2M-2-002, 2021-I2M-1-028, 2018ZX09711001-003-010, 82304585)
This publication has 64 references indexed in Scilit:
- FABP1 expression in human tumors: a tissue microarray study on 17,071 tumorsVirchows Archiv, 2022
- Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitisHepatology, 2022
- Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic reviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Pathogenesis of Nonalcoholic Steatohepatitis: An OverviewHepatology Communications, 2020
- Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR StudyHepatology, 2020
- Hepatocyte Deletion of Triglyceride‐Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in MiceHepatology, 2019
- Transcription factors CncC/Maf and AhR/ARNT coordinately regulate the expression of multiple GSTs conferring resistance to chlorpyrifos and cypermethrin in Spodoptera exiguaPest Management Science, 2019
- Fatty Acid Binding Protein‐1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and DyslipidemiasLipids, 2016
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983